Alpha DaRT Pembrolizumab Combo Shows 100% Response

Alpha Tau Medical reported positive data from a single-center study of Alpha DaRT combined with pembrolizumab in elderly patients with locally advanced or metastatic head and neck cancer, achieving a 100% systemic objective response rate and an 18.2-month median overall survival with no serious Alpha DaRT-related adverse events. The results, presented at the AHNS conference in Boston, exceeded historical pembrolizumab benchmarks and support continued trials and the company’s strategic push in immuno-oncology, with analyst notes highlighting a Buy rating for DRTS.